Back to Journals » OncoTargets and Therapy » Volume 10

Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer

Total article views   HTML views PDF downloads Totals
17,949 Dovepress* 12,710+ 1,745 14,455
PubMed Central* 5,239 1,026 6,265
Totals 17,949 2,771 20,720
*Since 19 June 2017
Total mentioned Facebook Delicious Reddit Twitter Others
5 0 0 0 0 5

View citations on PubMed Central and Google Scholar